KDR and plasma cell myeloma: In multiple myeloma patients, dovitinib and nintedanib, two multikinase inhibitors which inhibit FGFR, VEGFR, and PDGFR, have demonstrated little more than a tolerable safety profile and the potential to stabilize myelomatous disease (90, 91).